References
- Levy ML, Sheikh A, Walker S, Woods A. Should UK allergy focus on primary care? BMJ 2006;332:1347–8
- Varney VA, Gaga M, Frew AJ, Aber VR. Usefulness of immuno-therapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265–269
- Walker SM, Pajno GB, Lima MT, et al. Grass pollen immuno-therapy for seasonal rhinitis and asthma: a randomized controlled trial. J Allergy Clin Immunol 2001;107:87–93
- Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52:914–20
- Mosbech H, Østerballe O. Does the effect of immunotherapy last after termination of treatment? Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:523–9
- Durham SR, Waljer SM, Varga EM, Jacobson MR, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–75
- Hedlin G, Heilborn H, Lilja G, Norrlind K, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunology. J Allergy Clin Immunol 1995;96:879–85
- Möller C, Dreborg S, Ferdousi HA, Halken S, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis. The PAT-study. J Allergy Clin Immunol 2002;109:251–6
- Rakemann FM, Edwards RN. Asthma in children. A follow-up study of 688 patients after an interval of twenty years. N Engl J Med 1952;246:815–23
- Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr 1992;81: 100–2
- Berggren F, Hjelmgren J, Lindgren B. Differences in healthcare utilisation and workdays lost between individuals with and without asthma. Appl Health Econ Health Policy 2003;3:165–70
- World Health Organization (WHO) Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:1–42
- Frew AJ, Powell RJ, Corrigan CJ Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319–25
- Pedersen KD. Allergibehandling. En samfundsøkonomisk analyse i Århus Amt (In Danish: Allergy treatment. An economic analysis in Århus County). MPH thesis. Faculty of Medicine, Århus University
- Cost-effectiveness of immunotherapy with Alutard 100,000 SQ-U in patients with seasonal allergic rhinoconjunctivitis, Reports (a) Austria, (b) Denmark, (c) Finland, (d) Germany, (e) Netherlands, (f) Sweden. Muusmann Research & ALK-Abelló, 2004
- Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788–94
- National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal, NHS, April 2004
- Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108
- Pedersen KM, Wittrup-Jensen K, Brooks R, Gudex C. Værdisætning af sundhed. Teori om kvalitetsjusterede leveår (In Danish: Valuation of health. Theory of quality adjusted life years), Syddansk Universitetsforlag, Odense 2003
- Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149–53
- Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45–53
- Pajno GB, Barberio G, De Luca F, Morabito L, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392–7